Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Etanercept Market by Application (Arthritis, Psoriasis, Spondylitis): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03857

Pages: NA

Charts: NA

Tables: NA

Etanercept are biopharmaceutical anti-Tumor Necrosis Factor (TNF) that treats autoimmune diseases such as arthritis and spondylitis. Over production of TNF in the body causes inflammation, pain, and damage to the bones and joints. Etanercept blocks the action of TNF and reduces the inflammation. It is prescribed to treat juvenile rheumatoid arthritis, rheumatoid arthritis, and psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

Increase in prevalence of arthritis and spondylitis owing to the rise in incidences of obesity and accidents majorly drive the etanercept market. Furthermore, the increase in healthcare expenditure and awareness of arthritis by government private organizations is anticipated to increase the market growth. However, stringent government regulations associated with the safety and efficacy of etanercept hinder the market growth.

In addition, side effects of etanercept such as lowering ability of immune system, heart failure, seizers, blood problems, and others is anticipated to hinder the market growth. Ongoing R&D activities related to etanercept are anticipated to present new opportunities for the market.

The market is segmented on the basis of application and region. Based on application, it is categorized into Arthritis, Psoriasis, and Spondylitis. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global etanercept market with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to understand various products of the market.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market

 Key Market Segments

  • By Application
    • Arthritis
    • Psoriasis
    • Spondylitis
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Immunex Corporation
  • GlaxoSmithKline Pharmaceuticals Ltd
  • Cipla Limited
  • Takeda Pharmaceutical Company Ltd
  • Novartis International AG
  • Johnson and Johnson
  • Samsung Bioepis Co., Ltd.
  • Celltrion Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ETANERCEPT MARKET, BY APPLICATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Application

    • 4.2. Arthritis

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Psoriasis

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Spondylitis

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: ETANERCEPT MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Application

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Etanercept Market

        • 5.2.4.1. Market Size and Forecast, By Application

      • 5.2.5. Canada Etanercept Market

        • 5.2.5.1. Market Size and Forecast, By Application

      • 5.2.6. Mexico Etanercept Market

        • 5.2.6.1. Market Size and Forecast, By Application

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Application

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Etanercept Market

        • 5.3.4.1. Market Size and Forecast, By Application

      • 5.3.5. Germany Etanercept Market

        • 5.3.5.1. Market Size and Forecast, By Application

      • 5.3.6. Italy Etanercept Market

        • 5.3.6.1. Market Size and Forecast, By Application

      • 5.3.7. Spain Etanercept Market

        • 5.3.7.1. Market Size and Forecast, By Application

      • 5.3.8. UK Etanercept Market

        • 5.3.8.1. Market Size and Forecast, By Application

      • 5.3.9. Russia Etanercept Market

        • 5.3.9.1. Market Size and Forecast, By Application

      • 5.3.10. Rest Of Europe Etanercept Market

        • 5.3.10.1. Market Size and Forecast, By Application

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Application

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Etanercept Market

        • 5.4.4.1. Market Size and Forecast, By Application

      • 5.4.5. Japan Etanercept Market

        • 5.4.5.1. Market Size and Forecast, By Application

      • 5.4.6. India Etanercept Market

        • 5.4.6.1. Market Size and Forecast, By Application

      • 5.4.7. South Korea Etanercept Market

        • 5.4.7.1. Market Size and Forecast, By Application

      • 5.4.8. Australia Etanercept Market

        • 5.4.8.1. Market Size and Forecast, By Application

      • 5.4.9. Thailand Etanercept Market

        • 5.4.9.1. Market Size and Forecast, By Application

      • 5.4.10. Malaysia Etanercept Market

        • 5.4.10.1. Market Size and Forecast, By Application

      • 5.4.11. Indonesia Etanercept Market

        • 5.4.11.1. Market Size and Forecast, By Application

      • 5.4.12. Rest of Asia Pacific Etanercept Market

        • 5.4.12.1. Market Size and Forecast, By Application

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Application

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Etanercept Market

        • 5.5.4.1. Market Size and Forecast, By Application

      • 5.5.5. South Africa Etanercept Market

        • 5.5.5.1. Market Size and Forecast, By Application

      • 5.5.6. Saudi Arabia Etanercept Market

        • 5.5.6.1. Market Size and Forecast, By Application

      • 5.5.7. UAE Etanercept Market

        • 5.5.7.1. Market Size and Forecast, By Application

      • 5.5.8. Argentina Etanercept Market

        • 5.5.8.1. Market Size and Forecast, By Application

      • 5.5.9. Rest of LAMEA Etanercept Market

        • 5.5.9.1. Market Size and Forecast, By Application

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Pfizer Inc.

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Takeda Pharmaceutical Company Ltd

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Johnson And Johnson

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. GlaxoSmithKline Pharmaceuticals Ltd

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Samsung Bioepis Co., Ltd.

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. F. Hoffmann-La Roche Ltd

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. Cipla Limited

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Novartis International AG

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Celltrion Inc.

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Immunex Corporation

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ETANERCEPT MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ETANERCEPT MARKET FOR ARTHRITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ETANERCEPT MARKET FOR PSORIASIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ETANERCEPT MARKET FOR SPONDYLITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ETANERCEPT MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. NORTH AMERICA ETANERCEPT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. NORTH AMERICA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 8. U.S. ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 9. CANADA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 10. MEXICO ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 11. EUROPE ETANERCEPT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. EUROPE ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 13. FRANCE ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 14. GERMANY ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. ITALY ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 16. SPAIN ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. UK ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 18. RUSSIA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. REST OF EUROPE ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. ASIA-PACIFIC ETANERCEPT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. ASIA-PACIFIC ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. CHINA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. JAPAN ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. INDIA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. SOUTH KOREA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. AUSTRALIA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. THAILAND ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. MALAYSIA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. INDONESIA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. REST OF ASIA PACIFIC ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 31. LAMEA ETANERCEPT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 32. LAMEA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. BRAZIL ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. SOUTH AFRICA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. SAUDI ARABIA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. UAE ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 37. ARGENTINA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. REST OF LAMEA ETANERCEPT, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. PFIZER INC.: KEY EXECUTIVES
  • TABLE 40. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 41. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 42. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 43. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 44. TAKEDA PHARMACEUTICAL COMPANY LTD: KEY EXECUTIVES
  • TABLE 45. TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT
  • TABLE 46. TAKEDA PHARMACEUTICAL COMPANY LTD: OPERATING SEGMENTS
  • TABLE 47. TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO
  • TABLE 48. TAKEDA PHARMACEUTICAL COMPANY LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 49. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 50. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 51. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 52. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 53. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 54. GLAXOSMITHKLINE PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 55. GLAXOSMITHKLINE PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 56. GLAXOSMITHKLINE PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 57. GLAXOSMITHKLINE PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 58. GLAXOSMITHKLINE PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 59. SAMSUNG BIOEPIS CO., LTD.: KEY EXECUTIVES
  • TABLE 60. SAMSUNG BIOEPIS CO., LTD.: COMPANY SNAPSHOT
  • TABLE 61. SAMSUNG BIOEPIS CO., LTD.: OPERATING SEGMENTS
  • TABLE 62. SAMSUNG BIOEPIS CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 63. SAMSUNG BIOEPIS CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 64. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 65. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 66. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 67. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 68. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 69. CIPLA LIMITED: KEY EXECUTIVES
  • TABLE 70. CIPLA LIMITED: COMPANY SNAPSHOT
  • TABLE 71. CIPLA LIMITED: OPERATING SEGMENTS
  • TABLE 72. CIPLA LIMITED: PRODUCT PORTFOLIO
  • TABLE 73. CIPLA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 74. NOVARTIS INTERNATIONAL AG: KEY EXECUTIVES
  • TABLE 75. NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
  • TABLE 76. NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
  • TABLE 77. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
  • TABLE 78. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. CELLTRION INC.: KEY EXECUTIVES
  • TABLE 80. CELLTRION INC.: COMPANY SNAPSHOT
  • TABLE 81. CELLTRION INC.: OPERATING SEGMENTS
  • TABLE 82. CELLTRION INC.: PRODUCT PORTFOLIO
  • TABLE 83. CELLTRION INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. IMMUNEX CORPORATION: KEY EXECUTIVES
  • TABLE 85. IMMUNEX CORPORATION: COMPANY SNAPSHOT
  • TABLE 86. IMMUNEX CORPORATION: OPERATING SEGMENTS
  • TABLE 87. IMMUNEX CORPORATION: PRODUCT PORTFOLIO
  • TABLE 88. IMMUNEX CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ETANERCEPT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ETANERCEPT MARKET
  • FIGURE 3. SEGMENTATION ETANERCEPT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ETANERCEPT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALETANERCEPT MARKET
  • FIGURE 11. ETANERCEPT MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 12. ETANERCEPT MARKET FOR ARTHRITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ETANERCEPT MARKET FOR PSORIASIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ETANERCEPT MARKET FOR SPONDYLITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 16. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 17. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 18. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 19. COMPETITIVE DASHBOARD
  • FIGURE 20. COMPETITIVE HEATMAP: ETANERCEPT MARKET
  • FIGURE 21. TOP PLAYER POSITIONING, 2024
  • FIGURE 22. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 23. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 24. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 25. TAKEDA PHARMACEUTICAL COMPANY LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. TAKEDA PHARMACEUTICAL COMPANY LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. TAKEDA PHARMACEUTICAL COMPANY LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. GLAXOSMITHKLINE PHARMACEUTICALS LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. GLAXOSMITHKLINE PHARMACEUTICALS LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. GLAXOSMITHKLINE PHARMACEUTICALS LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. SAMSUNG BIOEPIS CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. SAMSUNG BIOEPIS CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. SAMSUNG BIOEPIS CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. CIPLA LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. CIPLA LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. CIPLA LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. NOVARTIS INTERNATIONAL AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. CELLTRION INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. CELLTRION INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. CELLTRION INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. IMMUNEX CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. IMMUNEX CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. IMMUNEX CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Etanercept Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved